Key result
In prostate cancer patients treated with radiotherapy or chemotherapy, PSA values >20 ng/mL and Gleason scores >7 were associated with increased risks of cardiovascular death.
Why the study?
The influence of tumor characteristics on cardiovascular death risk among prostate cancer patients who received radiotherapy or chemotherapy is often overlooked.
Are PSA values ≥10 ng/mL and Gleason scores >7 associated with an increased risk of cardiovascular death in prostate cancer patients after radiotherapy or chemotherapy?
Cohort (n=120,908)
Are PSA values ≥10 ng/mL and Gleason scores >7 associated with an increased risk of cardiovascular death in prostate cancer patients after radiotherapy or chemotherapy?
Higher PSA values and Gleason scores are associated with an increased risk of cardiovascular death in prostate cancer patients treated with radiotherapy or chemotherapy, highlighting the need for long-term cardiovascular monitoring in this population.
Answers are grounded in this paper and cite their sources.
May support intensified CV monitoring in high-risk prostate cancer; hypothesis-generating for risk stratification.
Background: Tumor characteristics are associated with the risk of cardiovascular death (CVD) in cancer patients. However, the influence of tumor characteristics on CVD risk among prostate cancer (PC) patients who have received radiotherapy (RT) or chemotherapy (CT) is often overlooked. This study explored the association between PC tumor characteristics and CVD risk in PC patients who had received RT or CT. Methods: Fine-gray competitive risk analysis was employed to identify CVD risk factors. Sensitivity analyses were conducted to adjust for confounding factors. The predicted prostate-specific antigen (PSA) and Gleason score values were visualized using a nomogram, which was subsequently validated through calibration curves and concordance indexes (C-indexes). Results: A total of 120,908 patients were enrolled in the study, with a mean follow-up time of 80 months. PSA values between 10 and 20 ng/mL (adjusted hazard ratio (HR): 1.28, 95% confidence interval (CI): 1.20–1.36, p < 0.001) and >20 ng/mL (adjusted HR: 1.27, 95% CI: 1.21–1.35, p < 0.001), and a Gleason score >7 (adjusted HR: 1.23, 95% CI: 1.07–1.41, p = 0.004) were identified as risk factors of CVD for PC patients after RT or CT. The C-index of the training cohort was 0.66 (95% CI: 0.66–0.67), and the C-index of the validation cohort was 0.67 (95% CI: 0.65–0.68). Consistency was observed between the actual observations and the nomogram. Risk stratification was also significant (p < 0.001). Conclusions: PSA values ≥10 ng/mL and Gleason scores >7 may be associated with an increased risk of CVD in PC patients after RT or CT. These patients may require more long-term follow-up and monitoring of CVD risk.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) conducted a cohort in Prostate cancer (n=120,908). Elevated Prostate-Specific Antigen (PSA) >20 ng/mL vs. PSA <10 ng/mL was evaluated on Cardiovascular death (CVD) (HR 1.27, 95% CI 1.21-1.35, p=<0.001). In prostate cancer patients treated with radiotherapy or chemotherapy, PSA values >20 ng/mL and Gleason scores >7 were associated with increased risks of cardiovascular death.
Synapse has enriched 10 related papers. Consider them for comparative context: